Department of Clinical Virology, Göteborg University, Guldhedsgatan 10B, 413 46 Göteborg, Sweden1
Author for correspondence: Magnus Lindh. Fax +46 31 827032. e-mail magnus.lindh{at}microbio.gu.se
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Mutations in other regions of the HBV genome, in particular the polymerase ORF, have been insufficiently studied. Because studies of mutations in the entire genome are rare, the frequency and importance of mutations in these coding regions are not known. Moreover, long-term longitudinal studies are largely lacking, due to the difficulty of sampling over long periods of time and, thus, the mutation rates in the different stages of HBV infection are not yet well established. So far, mutations have mainly been assessed in cross-sectional studies by comparison with a consensus sequence representing the serotype or genotype of the strain analysed, but it is not known to what extent this strategy reflects changes taking place during infection in a patient.
In the present study, we have examined the entire viral genome obtained from serum samples from three mothers with chronic HBV infection and their 10 adult children, who presumably were infected vertically and are now in different stages of chronic infection. By using these sequences, we have traced the likely original sequence that was probably transmitted at birth. Comparison of this sequence with the sequences now present in the mothers and children allowed a retrospective longitudinal analysis of rates and distribution of mutations that have emerged in the entire viral genome over periods of up to 35 years.
![]() |
Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
HBV DNA levels in serum were analysed by Amplicor HBV Monitor (Roche Diagnostic Systems) according to the manufacturers instructions. Samples with HBV DNA above the upper detection level (107·0 copies/ml) were reanalysed after dilution by 1:10000 in HBV-negative serum.
Histopathology and alanine aminotransferase (ALT) activity.
Liver damage was assessed by histology activity index (HAI) scoring in a blinded fashion (Knodell et al., 1981 ). ALT activities from an observation period of 110 years prior to liver biopsy were recorded.
Sequencing.
Overlapping segments covering the entire HBV genome were amplified by PCR with the primers described in Table 2. After gel-purification of PCR bands by using Qiaex (Qiagen), direct sequencing was carried out with the same primers as used for PCR. Each amplicon was analysed in both the sense and antisense directions after cycle sequencing reactions with fluorescent dye (Rhodamine; Applied Biosystems) terminators (ddNTPs). The sequence was read in an ABI Prism 310 automated capillary sequence reader (Applied Biosystems) and processed by using the Sequence Navigator software (Applied Biosystems).
|
The approach for longitudinal sequence analysis was based on three conditions: (i) that transmission took place perinatally, (ii) that the children were infected by the original strain and (iii) that there were no sequence changes during transmission, as indicated by nearly all previous transmission studies (see Günther et al., 1999 , pp. 36 and 50). To identify mutations that had emerged since transmission, the virus sequence now observed in each patient was compared with the probable sequence of the original strain of that family. This sequence is a consensus sequence of all sequences of a family and was deduced as follows. If three sequences were identical and one different in a specific position, the original sequence was based on that of the three sequences and the aberrant sequence was thus interpreted as a mutant at this position. If more than one sequence differed from the others at a specific nucleotide position, as was the case for three nucleotide positions in family 1 (Fam1) and for five nucleotide positions in Fam3, deduction of the original sequence was aided by hepatitis B e antigen (HBeAg) status and published sequence data: the nucleotides present in HBeAg-positive carriers were used in the deduced original sequence if present in at least 50% of published sequences, otherwise this position in the original sequence was considered uncertain.
The DNA sequence from each patient was also compared with a consensus sequence representing genotypes B (Fam2 and Fam3) or D (Fam1), as deduced from database sequences obtained from NCBI with the accession numbers D00329, D00330, D00331, D23678, D23679, D50521, D50522, M54923, X97850, X97851 and X98077 (genotype B) and J02203, L27106, M32138, U95551, X02496, Z35716, X85254 and X80925 (genotype D).
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The genetic difference between sequences within each family ranged from 0 to 0·84% of the whole genome. All three families clustered distinctly in phylogenetic tree analysis, as shown in Fig. 1.
|
|
The deletion in the pre-S region of nt 28542886, characteristic for genotype D, was present in all four cases.
Family 2
The mother (Fam2 Mo), aged 57, and all three children were HBeAg-positive with high virus loads and all had minimal or mild liver disease. The genomes in the mother and one child (Fam2 Ch2) showed no mutations, one child (Fam2 Ch1) had two mutations and one child (Fam2 Ch3) had one mutation (00·06%). Comparison with the genotype B consensus sequence indicated 5961 mutations in the entire genome (about 1·8%), a significant overestimate of the mutations that had emerged during infection.
Family 3
At the time of sampling, the mother (Fam3 Mo) was HBeAg-negative and had severe liver damage with active cirrhosis. Four years later, at the age of 61, she developed hepatocellular carcinoma and died. One of the children was a highly viraemic (HBeAg-positive), asymptomatic carrier, one had a relatively mild HBeAg-negative hepatitis with a low level of virus replication and two were low-viraemic, healthy carriers.
In five positions, the virus genome from more than one subject in family 3 had a nucleotide that diverged from the other sequences, and therefore the original sequence was not apparent. In these five positions, sequences from Fam3 Ch2 and Fam3 Ch3 were identical, as were sequences from Fam3 Mo, Fam3 Ch1 and Fam3 Ch4. The probable original sequence in four of these positions was deduced from the sequence in the HBeAg-positive carrier (Fam3 Ch2), in agreement with most published genotype B sequences (92% agreement at nt 167, 2304 and 2525, 100% at nt 1128), and was considered uncertain in one position (33% agreement at nt 2712).
Mutations were not detected in the HBeAg-positive subject (Fam3 Ch2), but were detected in all four HBeAg-negative subjects, with a total number of mutations ranging from 15 to 27, and a similar frequency in the various genomic regions (Table 1; Figs 2
and 3
).
|
|
Mutations in relation to clinical stage and disease
The distribution of mutations in the genome is indicated in Fig. 2 and the resulting amino acid substitutions are described in Fig. 3
and Table 3
. The eight HBeAg-positive carriers, with a mean observation period of 24·4 years, showed a mean of 1·6 mutations (0·05 %) in the whole genome, compared to a mean of 20 mutations (0·62%) in five HBeAg-negative carriers with a mean observation period of 27·6 years (P<0·0001; Fishers exact test). Silent mutations were rare and the majority (88%) of the mutations resulted in amino acid substitutions in at least one and in some cases (13%) in two (i.e. overlapping) ORFs.
The individual sequences were also compared with the consensus sequences representing the corresponding genotypes (as obtained from NCBI database sequences), giving nucleotide differences ranging from 1·6 to 2·4%. A large proportion of these differences, especially in HBeAg-positive carriers, appeared not to represent mutations that had emerged in the patient during the course of infection.
The total number of mutations (n=9) was higher in the HBeAg-positive patient with chronic active hepatitis compared with the seven HBeAg-positive carriers with mild or minimal inflammation (02 mutations, mean=0·63). In the five HBeAg-negative patients, the total number of mutations was not significantly higher in the two patients with severe liver damage (19 and 27 mutations) compared with the three patients with mild liver disease (15, 19 and 20 mutations). Moreover, the distribution of mutations between the different genomic regions and ORFs seemed not to be associated with the degree of liver damage.
Four of the five HBeAg-negative patients had a GA mutation at nt 1896, creating a premature stop codon. Only one of these, Fam1 Mo, had severe liver damage. She also had a high level of viraemia (108·2 copies/ml). One further HBeAg-negative patient (Fam3 Mo) had severe liver damage, but showed a pre-core wild-type sequence and moderate viraemia (105·5 copies/ml).
In the pre-S region, no mutations were found in any of the eight HBeAg-positive carriers, while each of the five HBeAg-negative had at least three mutations. One patient with mild liver damage (Fam3 Ch3) showed two mutations (D39N, L45
F) within the putative receptor-binding region (aa 2147; Neurath et al., 1986
).
In the S region, the four HBeAg-negative patients in family 3 showed mutations at sites linked to w/r seroreactivity (Okamoto et al., 1986 ); in two of them within (T126
A), and in two outside (I110
L and Y161
F), the a-determinant loop. Fam3 Mo showed an N
S mutation at aa 40, which was recently reported as being frequent in patients with hepatocellular carcinoma and adw subtype infection (Tai et al., 1997
).
In the X region, missense mutations were found at positions previously described as mutation sites (Uchida et al., 1997 ), including the K130
M/V131
I double mutation. This AGG
TGA mutation at nt 17621764 in the part of the X ORF that contains the core promoter was observed in both of the HBeAg-negative patients with severe liver damage (active cirrhosis) but in none of the other patients.
There was no apparent association between mutations in the core region and clinical status. The two HBeAg-negative patients with active cirrhosis had six and five mutations, while the three with mild liver damage had six, four and two mutations. A tendency towards clustering in the region from aa 135 to 149 was seen, including four patients with mutations at aa 135. Mutations were relatively more frequent in the putative CTL epitope at aa 141151 (P=0·04, Fishers exact test) and tended to be more frequent in the B-cell epitope at aa 120140 (P=0·06) than elsewhere in the core. T147C within the CTL epitope was seen only in the two mothers with active cirrhosis.
Mutations were found in all parts of the pol ORF, but were rarer carboxy-terminal of aa 490. Substitutions were seen in three or four of five subjects in family 3 at aa 73, 136, 359, 480 and 679.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The stage-dependent mutation rate in chronic hepatitis B, with few mutations in the HBeAg-positive tolerance phase, has been demonstrated in several previous cross-sectional studies (Akarca & Lok, 1995 ; Karasawa et al., 1997
). Longitudinal analyses of the entire genome are lacking, probably because long observation periods are rare. The retrospective approach of the present study provides observation periods equal to the age of the offspring and should be a useful complement for studies of long-term mutation rates in chronic hepatitis B. A similar intrafamilial comparison of the genome has been used in one previous study of mutations in the core region (Bozkaya et al., 1997
).
In cross-sectional studies, mutations are sometimes identified by comparing the observed sequence to database sequences of the same genotype. The present study describes the degree of overestimation if this method is used for assessing mutations in individual patients. For example, in four HBeAg-positive carriers with completely unchanged genomes over 2035 years, a database comparison would indicate 5059 mutations. Still, comparison with carefully selected reference sequences in cross-sectional studies appears to identify the same mutation hot-spot positions as longitudinal studies, at least in the core region, as was shown in a recent analysis of compiled data (Günther et al., 1999 ). This indicates that mutations are localized primarily to positions where they are not harmful, not necessarily reflecting the major target antigens or epitopes. This is supported indirectly by the recent observation that the majority of single point mutations, introduced randomly into the HBV genome by PCR, render the virus replication-incompetent (Günther et al., 1998c
).
In the present study, clustering of mutations could not be analysed adequately due to the relatively small number of patients. However, the observation that mutations were distributed over the entire genome without an apparent concentration to certain regions suggests that the various proteins may be of similar importance as immune targets. In the second half of the Pol region, where the intergenotypic variability is low and where the active sites for reverse transcriptase/polymerase and RNase functions probably reside (Radziwill et al., 1990 ), the mutation frequency was lower, but this may simply reflect the fact that mutations in this region are likely to be deleterious to the virus and this observation cannot be interpreted as meaning that this region is less immunologically important.
Analysing the pathogenic importance of individual mutations was not the major topic of this work. However, the double mutation at nt 17621764 (AGGTGA) was only seen in the two patients (Fam1 Mo and Fam3 Mo) with active cirrhosis, in agreement with previous reports associating this mutation with more severe liver damage (Takahashi et al., 1995
; Lindh et al., 1999
). The emergence of this mutation may be due to its location in the core promoter and its effects on transcription of pre-core/core mRNA and/or virus replication (Moriyama et al., 1996
; Buckwold et al., 1997
; Günther et al., 1998b
), but also to the K130
M and V131
I substitutions in the X protein (Li et al., 1999
).
Mutations were also seen in other parts of the X region at mutation sites described previously (Uchida et al., 1997 ). These included mutations at nt 1630 and 1632 in the negative regulatory element, at nt 1655 in enhancer 2 and at nt 1752, 1753 and 1757 in the basal core promoter. More knowledge of the function of the X protein and the regulatory sequences is required in order to interpret these mutations.
A TAG stop mutation at codon 28 in the pre-core region was seen in three patients (Fam3 Ch1, Ch3 and Ch4) with low levels of viraemia and minimal or mild inflammation and in two patients (Fam1 Mo and Ch3) with high virus loads and severe inflammation of the liver. This agrees with the view that the severe liver damage seen in some patients with pre-core mutant infection is not due to the mutation per se, but to the high virus load that may occur despite the absence of the general marker for active infection, HBeAg, in the serum. One further HBeAg-negative patient (Fam3 Mo) had active cirrhosis but had a much lower level of viraemia; she had no pre-core mutation preventing HBeAg synthesis. In the core region, the number of mutations did not differ between HBeAg-negative patients with mild or severe liver disease, in agreement with previous reports (Akarca & Lok, 1995 ; Karasawa et al., 1997
). Mutations were relatively more frequent in the putative CTL epitope at aa 141151 and in the B-cell epitope at aa 120140. Mutations at nt 135 and 147, which have also been observed by others (Akarca & Lok, 1995
; Carman et al., 1997
), were found in four and two patients, respectively (Table 3
). Mutations in the S region have mainly been studied previously in the context of serotype characteristics (Okamoto et al., 1987
), vaccine escape (Carman et al., 1990
) and HBsAg-negative HBV infection (Zhang et al., 1996
). In four of five HBeAg-negative patients, we found mutations resulting in substitutions of amino acids that are linked to w/r seroreactivity and genotype; in the a-determinant loop in Fam3 Mo and Fam3 Ch1 (T126
A) and in flanking regions in Fam3 Ch3 (I110
L) and Fam3 Ch4 (Y161
F). Furthermore, an N40
S mutation, which has been reported as frequent in Japanese adw carriers with hepatocellular carcinoma (Tai et al., 1997
), was seen in one patient (Fam3 Mo) with active cirrhosis who later developed hepatocellular carcinoma.
To our knowledge, no previous study has analysed natural mutations longitudinally in the entire HBV genome. In a basically cross-sectional study of six patients (including follow-up samples from two patients after 5 months and after 3 years), Horikita et al. (1994) found a similar number and distribution of mutations in various parts of the genome in HBeAg-negative patients as in the present study. In a longitudinal study of a patient treated with interferon, Günther et al. (1998a
) found a predominance of mutations in the core region versus other parts of the genome.
In summary, we present the retrospective analysis of the genomic divergence of HBV within families as a feasible means of studying mutations longitudinally in chronic hepatitis B and demonstrate that the entire HBV genome is extremely stable in the early high-replicative phase, when the immune response is considered to be weak. We also describe the degree of overestimation of mutation rates when assessed by comparison with database sequences and show that mutations are distributed fairly evenly in all coding regions. Further longitudinal study is needed to establish mutation rates and to identify clustering in the various genomic regions and to analyse whether natural and interferon-induced genetic variability differ in this respect.
![]() |
Acknowledgments |
---|
![]() |
Footnotes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bozkaya, H., Akarca, U. S., Ayola, B. & Lok, A. S. (1997). High degree of conservation in the hepatitis B virus core gene during the immune tolerant phase in perinatally acquired chronic hepatitis B virus infection. Journal of Hepatology 26, 508-516.[Medline]
Buckwold, V. E., Xu, Z., Yen, T. S. B. & Ou, J.-h. (1997). Effects of a frequent double-nucleotide basal core promoter mutation and its putative single-nucleotide precursor mutations on hepatitis B virus gene expression and replication. Journal of General Virology 78, 2055-2065.[Abstract]
Carman, W. F., Jacyna, M. R., Hadziyannis, S., Karayiannis, P., McGarvey, M. J., Makris, A. & Thomas, H. C. (1989). Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet ii, 588591.
Carman, W. F., Zanetti, A. R., Karayiannis, P., Waters, J., Manzillo, G., Tanzi, E., Zuckerman, A. J. & Thomas, H. C. (1990). Vaccine-induced escape mutant of hepatitis B virus. Lancet 336, 325-329.[Medline]
Carman, W. F., Boner, W., Fattovich, G., Colman, K., Dornan, E. S., Thursz, M. & Hadziyannis, S. (1997). Hepatitis B virus core protein mutations are concentrated in B cell epitopes in progressive disease and in T helper cell epitopes during clinical remission. Journal of Infectious Diseases 175, 1093-1100.[Medline]
Felsenstein, J. (1993). PHYLIP (Phylogeny Inference Package) version 3.5c. Distributed by the author. Department of Genetics, University of Washington, Seattle, WA, USA.
Günther, S., Paulij, W., Meisel, H. & Will, H. (1998a). Analysis of hepatitis B virus populations in an interferon--treated patient reveals predominant mutations in the C-gene and changing e-antigenicity. Virology 244, 146-160.[Medline]
Günther, S., Piwon, N. & Will, H. (1998b). Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653)T, A(1762)
T and G(1764)
A mutations in the core promoter. Journal of General Virology 79, 375-380.[Abstract]
Günther, S., Sommer, G., Von Breunig, F., Iwanska, A., Kalinina, T., Sterneck, M. & Will, H. (1998c). Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations. Journal of Clinical Microbiology 36, 531-538.
Günther, S., Fischer, L., Pult, I., Sterneck, M. & Will, H. (1999). Naturally occurring variants of hepatitis B virus. Advances in Virus Research 52, 25-137.[Medline]
Horikita, M., Itoh, S., Yamamoto, K., Shibayama, T., Tsuda, F. & Okamoto, H. (1994). Differences in the entire nucleotide sequence between hepatitis B virus genomes from carriers positive for antibody to hepatitis B e antigen with and without active disease. Journal of Medical Virology 44, 96-103.[Medline]
Karasawa, T., Shirasawa, T., Okawa, Y., Kuramoto, A., Shimada, N., Aizawa, Y., Zeniya, M. & Toda, G. (1997). Association between frequency of amino acid changes in core region of hepatitis B virus (HBV) and the presence of precore mutation in Japanese HBV carriers. Journal of Gastroenterology 32, 611-622.[Medline]
Knodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W. & Wollman, J. (1981). Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1, 431-435.[Medline]
Li, J., Buckwold, V. E., Hon, M. W. & Ou, J. H. (1999). Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. Journal of Virology 73, 1239-1244.
Lindh, M., Horal, P., Dhillon, A. P., Furuta, Y. & Norkrans, G. (1996). Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage. Hepatology 24, 494-501.[Medline]
Lindh, M., Andersson, A. S. & Gusdal, A. (1997). Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus large-scale analysis using a new genotyping method. Journal of Infectious Diseases 175, 1285-1293.[Medline]
Lindh, M., Hannoun, C., Dhillon, A. P., Norkrans, G. & Horal, P. (1999). Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. Journal of Infectious Diseases 179, 775-782.[Medline]
Lok, A. S., Akarca, U. & Greene, S. (1994). Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proceedings of the National Academy of Sciences, USA 91, 4077-4081.[Abstract]
Moriyama, K., Okamoto, H., Tsuda, F. & Mayumi, M. (1996). Reduced precore transcription and enhanced corepregenome transcription of hepatitis B virus DNA after replacement of the precorecore promoter with sequences associated with e antigen-seronegative persistent infections. Virology 226, 269-280.[Medline]
Neurath, A. R., Kent, S. B., Strick, N. & Parker, K. (1986). Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46, 429-436.[Medline]
Okamoto, H., Imai, M., Shimozaki, M., Hoshi, Y., Iizuka, H., Gotanda, T., Tsuda, F., Miyakawa, Y. & Mayumi, M. (1986). Nucleotide sequence of a cloned hepatitis B virus genome, subtype ayr: comparison with genomes of the other three subtypes. Journal of General Virology 67, 2305-2314.[Abstract]
Okamoto, H., Imai, M., Tsuda, F., Tanaka, T., Miyakawa, Y. & Mayumi, M. (1987). Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. Journal of Virology 61, 3030-3034.[Medline]
Okamoto, H., Tsuda, F., Akahane, Y., Sugai, Y., Yoshiba, M., Moriyama, K., Tanaka, T., Miyakawa, Y. & Mayumi, M. (1994). Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. Journal of Virology 68, 8102-8110.[Abstract]
Radziwill, G., Tucker, W. & Schaller, H. (1990). Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. Journal of Virology 64, 613-620.[Medline]
Tai, P. C., Banik, D., Lin, G. I., Pai, S., Pai, K., Lin, M. H., Yuoh, G., Che, S., Hsu, S. H., Chen, T. C., Kuo, T. T., Lee, C. S., Yang, C. S. & Shih, C. (1997). Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. Journal of Virology 71, 4852-4856.[Abstract]
Takahashi, K., Aoyama, K., Ohno, N., Iwata, K., Akahane, Y., Baba, K., Yoshizawa, H. & Mishiro, S. (1995). The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. Journal of General Virology 76, 3159-3164.[Abstract]
Uchida, T., Saitoh, T. & Shinzawa, H. (1997). Mutations of the X region of hepatitis B virus and their clinical implications. Pathology International 47, 183-193.[Medline]
Zhang, Y. Y., Nordenfelt, E. & Hansson, B. G. (1996). Increasing heterogeneity of the a determinant of HBsAg found in the presumed late phase of chronic hepatitis B virus infection. Scandinavian Journal of Infectious Diseases 28, 9-15.[Medline]
Received 26 July 1999;
accepted 21 September 1999.